{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:55:43Z","timestamp":1793350543360,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as neoadjuvant or adjuvant treatment for breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical data of invasive breast cancer patients who received neoadjuvant or adjuvant chemotherapy with PLD or epirubicin were retrospectively collected. Propensity score matching (PSM) was performed to reduce the risk of selection bias. The molecular typing of these patients included Luminal A, Luminal B, HER2-positive, and basal-like\/triple-negative. The primary outcome was pathological complete response (pCR) rate for neoadjuvant chemotherapy and 3-year disease-free survival (DFS) rate for adjuvant chemotherapy. Noninferiority was suggested if the lower limit of the 95% CI for the 3-year DFS rate difference was greater than \u2212\u200910%. The secondary outcome was adverse reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1213 patients were included (neoadjuvant, <jats:italic>n<\/jats:italic>\u2009=\u2009274; adjuvant, <jats:italic>n<\/jats:italic>\u2009=\u2009939). pCR (ypT0\/Tis ypN0) rates of patients who received neoadjuvant chemotherapy were 11.6% for the PLD group and 7.0% for the epirubicin group, but the difference was not statistically significant (<jats:italic>P<\/jats:italic>\u2009=\u20090.4578). The 3-year DFS rate of patients who received adjuvant chemotherapy was 94.9% [95%CI, 91.1\u201398.6%] for the PLD group and 95.4% [95%CI, 93.0\u201397.9%] for the epirubicin group (<jats:italic>P<\/jats:italic>\u2009=\u20090.5684). Rate difference between the two groups and its 95% CI was - 0.55 [\u2212\u20095.02, 3.92]. The lower limit of the 95% CI was \u2212\u20095.0%\u2009&gt;\u2009\u2212\u200910.0%, suggesting that PLD is not be inferior to epirubicin in adjuvant chemotherapy for breast cancer. The incidences of myelosuppression, decreased appetite, alopecia, gastrointestinal reactions, and cardiotoxicity were lower in the PLD group than in the epirubicin group, while the incidence of nausea was higher in the PLD group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the neoadjuvant and adjuvant treatment of breast cancer, effectiveness is similar but toxicities are different between the\u00a0PLD-containing regimen\u00a0and epirubicin-containing regimen. Therefore, further study is warranted to explore PLD-based neoadjuvant and adjuvant chemotherapy for breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09050-6","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:02:53Z","timestamp":1638795773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"9050_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"9050_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11864-018-0538-9","volume":"19","author":"T Reinert","year":"2018","unstructured":"Reinert T, Gon\u00e7alves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast Cancer. Curr Treat Options in Oncol. 2018;19:23.","journal-title":"Curr Treat Options in Oncol"},{"key":"9050_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00000421-198710000-00005","volume":"10","author":"SE Jones","year":"1987","unstructured":"Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol. 1987;10:387\u201395.","journal-title":"Am J Clin Oncol"},{"key":"9050_CR4","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 1.2021). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"9050_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdn728","volume":"20","author":"PJ Barrett-Lee","year":"2009","unstructured":"Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20:816\u201327.","journal-title":"Ann Oncol"},{"key":"9050_CR6","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"9050_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.","journal-title":"Front Cardiovasc Med"},{"key":"9050_CR8","doi-asserted-by":"publisher","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","volume":"9","author":"MW Bloom","year":"2016","unstructured":"Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9:e002661.","journal-title":"Circ Heart Fail"},{"key":"9050_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19:9\u201342.","journal-title":"Eur J Heart Fail"},{"key":"9050_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","volume":"18","author":"D Cardinale","year":"2016","unstructured":"Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep. 2016;18:51.","journal-title":"Curr Cardiol Rep"},{"key":"9050_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mpo.2950240604","volume":"24","author":"LJ Steinherz","year":"1995","unstructured":"Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352\u201361.","journal-title":"Med Pediatr Oncol"},{"key":"9050_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440\u20139.","journal-title":"Ann Oncol"},{"key":"9050_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1756-9966-30-39","volume":"30","author":"P Vici","year":"2011","unstructured":"Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, et al. A multicenter prospective phase II randomized trial of epirubicin\/vinorelbine versus pegylated liposomal doxorubicin\/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res. 2011;30:39.","journal-title":"J Exp Clin Cancer Res"},{"key":"9050_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000498993","volume":"42","author":"M Cheng","year":"2019","unstructured":"Cheng M, Song Z, Qi Y, Wang X, Zhang L, Shi J, et al. A dose-escalating pilot study (NCT03017404) of Pegylated liposomal doxorubicin and cyclophosphamide, followed by docetaxel administration as a neoadjuvant chemotherapy regimen in patients with locally advanced breast Cancer. Oncol Res Treat. 2019;42:269\u201374.","journal-title":"Oncol Res Treat"},{"key":"9050_CR15","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.1038\/s41598-019-54387-5","volume":"9","author":"R Li","year":"2019","unstructured":"Li R, Tian F, Qi Y, Ma L, Zhou T, Li Y, et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). Sci Rep. 2019;9:18135.","journal-title":"Sci Rep"},{"key":"9050_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/annonc\/mdr519","volume":"23","author":"D Rayson","year":"2012","unstructured":"Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, et al. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol. 2012;23:1780\u20138.","journal-title":"Ann Oncol"},{"key":"9050_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206\u201323.","journal-title":"Ann Oncol"},{"key":"9050_CR18","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M, Schl\u00fcter G, Schmidt A, Rosenberger A, et al. NAD(P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754\u201362.","journal-title":"Circulation"},{"key":"9050_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"9050_CR20","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/jco.2011.29.15_suppl.1028","volume":"29","author":"GV Minckwitz","year":"2011","unstructured":"Minckwitz GV, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol. 2011;29:1028.","journal-title":"J Clin Oncol"},{"key":"9050_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1517\/14656566.6.9.1477","volume":"6","author":"EO Hanrahan","year":"2005","unstructured":"Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 2005;6:1477\u201391.","journal-title":"Expert Opin Pharmacother"},{"key":"9050_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.breast.2016.07.017","volume":"29","author":"MS van Ramshorst","year":"2016","unstructured":"van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentj\u00e9 VO, Oving IM, Mandjes IA, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study. Breast. 2016;29:153\u20139.","journal-title":"Breast"},{"key":"9050_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170:559\u201367.","journal-title":"Breast Cancer Res Treat"},{"key":"9050_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/1120009X.2020.1746886","volume":"32","author":"J Yao","year":"2020","unstructured":"Yao J, Pan S, Fan X, Jiang X, Yang Y, Jin J, et al. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer. J Chemother. 2020;32:202\u20137.","journal-title":"J Chemother"},{"key":"9050_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40261-018-0655-z","volume":"38","author":"EC Tampaki","year":"2018","unstructured":"Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, et al. Efficacy and safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally\/regionally advanced, HER2-negative, grade III at premenopausal status breast Cancer: a phase II study. Clin Drug Investig. 2018;38:639\u201348.","journal-title":"Clin Drug Investig"},{"key":"9050_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","volume":"151","author":"MJ Gil-Gil","year":"2015","unstructured":"Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015;151:597\u2013606.","journal-title":"Breast Cancer Res Treat"},{"key":"9050_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3109\/0284186X.2014.921727","volume":"53","author":"MK Tuxen","year":"2014","unstructured":"Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide \u00b1 trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014;53:1440\u20135.","journal-title":"Acta Oncol"},{"key":"9050_CR28","first-page":"3817","volume":"30","author":"G Artioli","year":"2010","unstructured":"Artioli G, Mocellin S, Borgato L, Cappetta A, Bozza F, Zavagno G, et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res. 2010;30:3817\u201321.","journal-title":"Anticancer Res"},{"key":"9050_CR29","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2147\/OTT.S162003","volume":"11","author":"M Dong","year":"2018","unstructured":"Dong M, Luo L, Ying X, Lu X, Shen J, Jiang Z, et al. Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study. Onco Targets Ther. 2018;11:4247\u201352.","journal-title":"Onco Targets Ther"},{"key":"9050_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","volume":"1","author":"T Fujii","year":"2015","unstructured":"Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, et al. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast Cancer: a systematic review and Network Meta-analysis. JAMA Oncol. 2015;1:1311\u20138.","journal-title":"JAMA Oncol"},{"key":"9050_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdu007","volume":"25","author":"J Bines","year":"2014","unstructured":"Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo\/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol. 2014;25:1079\u201385.","journal-title":"Ann Oncol"},{"key":"9050_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","volume":"13","author":"J Anampa","year":"2015","unstructured":"Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195.","journal-title":"BMC Med"},{"key":"9050_CR33","doi-asserted-by":"publisher","first-page":"e12908","DOI":"10.1097\/MD.0000000000012908","volume":"97","author":"W Ding","year":"2018","unstructured":"Ding W, Li Z, Wang C, Dai J, Ruan G, Tu C. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e12908.","journal-title":"Medicine (Baltimore)"},{"key":"9050_CR34","first-page":"1367","volume":"18","author":"DK Tack","year":"2004","unstructured":"Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology (Williston Park). 2004;18:1367\u201376 discussion 1378, 1381.","journal-title":"Oncology (Williston Park)"},{"key":"9050_CR35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/bjc.2012.370","volume":"107","author":"HM Earl","year":"2012","unstructured":"Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, et al. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT\/BR9601 trials. Br J Cancer. 2012;107:1257\u201367.","journal-title":"Br J Cancer"},{"key":"9050_CR36","first-page":"159","volume":"30","author":"YC Lu","year":"2016","unstructured":"Lu YC, Ou-Yang FU, Hsieh CM, Chang KJ, Chen DR, Tu CW, et al. Pegylated liposomal doxorubicin as adjuvant therapy for stage I-III operable breast Cancer. In Vivo. 2016;30:159\u201363.","journal-title":"In Vivo"},{"key":"9050_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ajco.12771","volume":"14","author":"FO Yang","year":"2018","unstructured":"Yang FO, Hsu NC, Moi SH, Lu YC, Hsieh CM, Chang KJ, et al. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. Asia Pac J Clin Oncol. 2018;14:198\u2013203.","journal-title":"Asia Pac J Clin Oncol"},{"key":"9050_CR38","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","volume":"27","author":"JA Sparano","year":"2009","unstructured":"Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27:4522\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09050-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:06:51Z","timestamp":1638796011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9050"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09050-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Administration Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and conducted in accordance with the Principles of Helsinki Declaration. Patient consent was exempt because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1301"}}